Let not forget the strong uptake of SPP considering the current stock price , or the institutional and insider buying in the second half of the year, no one likes to lose money and there would of been some strong fundamental analysis prior to buying which is bullish despite the stock price. If it were not for the timing of the CR the stock price would be a lot higher that it is currently . The next couple quarters are going very important for oncosil and investors.
OncoSil Medical Ltd has announced a significant change in the shareholding interests of Director Douglas Cubbin, who acquired an additional 25 million shares and 32.5 million options.
Douglas Cubbin Non-Executive Chairman of the OncoSil Board. His tenure as Chairman began in August 2023, following the retirement of Otto Buttula. Cubbin brings over 30 years of experience in senior executive roles, including CFO, Director, and Chair positions across various industries. Notably, he was involved in significant corporate growth and IPO processes during his time as Group Chief Financial Officer at Telix Pharmaceuticals Limited (ASX:TLX). Before joining OncoSil, he also served as Chairman of various boards, including the Australian Nuclear Science and Technology Organisation (ANSTO) Nuclear Medicine
The SPP raised a total of $1 million. The total amount raised comprised 69 million NewShares and 69 million New Options issued to existing Eligible Shareholders under the SPPOffer and 31 million New Shares and 31 million New Options were issued under the SPPShortfall Commitment. The Company has also secured a commitment froman institution for any shortfall securities arising from the share purchase plan. When Nigel was asked in previous presentation if I remember correctly , he would not confirm or deny if it was the same institution who was involved in the previous institutional investment which sounded like he answered the question by making that comment , just an opinion .
$2.7 million Institutional investment announced in July this year before costs via the issue of approximately 386 million new fully paidordinary shares in the Company (New Shares) at $0.007 per New Share (Offer Price) together with oneOSLOB Short Dated Listed Option (expiry date 30 June 2025, exercise price $0.009 ea.)
OSL Price at posting:
0.7¢ Sentiment: Buy Disclosure: Held
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
(20min delay)